Skip to main content
SpringerLink
Log in

Protective Effect of Resveratrol Combined with Levodopa Against Oxidative Damage in Dopaminergic Neurons

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Levodopa (L-3,4-dihydroxyphenylalanine, L-Dopa) alleviates the symptoms of Parkinson’s disease (PD), yet prolonged usage may give rise to severe adverse effects. Resveratrol (RSV) is a potent antioxidant, anticancer and anti-inflammatory agent. And a variety of polyphenol antioxidant compounds derived from RSV combined with levodopa have demonstrated neuroprotective activity against neuronal cell death. The purpose of this study was to examine the impact of this combination of RSV and L-Dopa on the survival rate, growth status, and reactive oxygen species (ROS) of MES23.5 dopamine (DA) neuron cells. In this study, we induced MPP+ in MES23.5 dopamine neuron cells and observed their survival rate, growth status, ROS content, as well as the effect of RSV combined with L-Dopa on cell survival. We also measured malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity levels as indicators of mitochondrial function, oxidative stress, and oxidative damage in the cells. Our results indicated that the MES23.5 dopamine neurons had decreased survival, poor growth status, and increased ROS content after MPP+ induction. Moreover, we found that MDA levels were elevated, and SOD activity levels were decreased, suggesting that the cells experienced abnormal mitochondrial function. However, when RSV was combined with L-Dopa, the cells showed a reduced level of MPP + -induced oxidative damage, with a more significant inhibitory effect observed in the RSV group at a concentration of 50 μmol/L. In conclusion, we found that the effects of co-administration of RSV with L-Dopa (100 μmol/L) was more effective than L-Dopa administered at the high dose. Thus, we found that RSV has the potential to reduce the dose of L-Dopa required to improve PD symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

No datasets were generated or analyzed during the current study.

References

  1. Trist, B. G., Hare, D. J., & Double, K. L. (2019). Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell, 18, e13031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jiang, T., Sun, Q., & Chen, S. (2016). Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Progess in Neurobiology, 147, 1–19.

    Article  CAS  Google Scholar 

  3. Ding, C., Ganesvaran, G., Alty, J. E., Clissold, B. G., McColl, C. D., & Reardon, K. A., et al. (2016). Study of levodopa response in Parkinson’s disease: observations on rates of motor progression. Movement Disorders, 31, 589–592.

    Article  CAS  PubMed  Google Scholar 

  4. Gong, P., Deng, F., Zhang, W., Ji, J., Liu, J., & Sun, Y., et al. (2017). Tectorigenin attenuates the MPP(+)-induced SH-SY5Y cell damage, indicating a potential beneficial role in Parkinson’s disease by oxidative stress inhibition. Experimental and Therapeutic Medicine, 14, 4431–4437.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. The New England Journal of Medicine, 276, 374–379.

    Article  CAS  PubMed  Google Scholar 

  6. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. Lancet, 397, 2284–2303.

    Article  CAS  PubMed  Google Scholar 

  7. Borah, A., & Mohanakumar, K. P. (2009). Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. Journal of Pineal Research, 47, 293–300.

    Article  CAS  PubMed  Google Scholar 

  8. Zou, L., Jankovic, J., Rowe, D. B., Xie, W., Appel, S. H., & Le, W. (1999). Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sciences, 64, 1275–1285.

    Article  CAS  PubMed  Google Scholar 

  9. Naskar, A., Prabhakar, V., Singh, R., Dutta, D., & Mohanakumar, K. P. (2015). Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Journal of Pineal Research, 58, 262–274.

    Article  CAS  PubMed  Google Scholar 

  10. Ji, H., Zhang, X., Du, Y., Liu, H., Li, S., & Li, L. (2012). Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Research Bulletin, 87, 50–59.

    Article  CAS  PubMed  Google Scholar 

  11. Liu, Q., Zhu, D., Jiang, P., Tang, X., Lang, Q., & Yu, Q., et al. (2019). Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behavioural Brain Research, 367, 10–18.

    Article  CAS  PubMed  Google Scholar 

  12. Jin, F., Wu, Q., Lu, Y. F., Gong, Q. H., & Shi, J. S. (2008). Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. European Journal of Pharmacology, 600, 78–82.

    Article  CAS  PubMed  Google Scholar 

  13. Su, C. F., Jiang, L., Zhang, X. W., Iyaswamy, A., & Li, M. (2021). Resveratrol in rodent models of Parkinson’s disease: A systematic review of experimental studies. Frontiers in Pharmacology, 12, 644219.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Arbo, B. D., André-Miral, C., Nasre-Nasser, R. G., Schimith, L. E., Santos, M. G., & Costa-Silva, D., et al. (2020). Resveratrol derivatives as potential treatments for Alzheimer’s and Parkinson’s disease. Frontiers in Aging Neuroscience, 12, 103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chao, J., Li, H., Cheng, K. W., Yu, M. S., Chang, R. C., & Wang, M. (2010). Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Journal of Nutritional Biochemistry, 21, 482–489.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang, Q., Yuan, L., Zhang, Q., Gao, Y., Liu, G., & Xiu, M., et al. (2015). Resveratrol attenuates hypoxia-induced neurotoxicity through inhibiting microglial activation. International Immunopharmacology, 28, 578–587.

    Article  CAS  PubMed  Google Scholar 

  17. Gong, C., & Xia, H. (2020). Resveratrol suppresses melanoma growth by promoting autophagy through inhibiting the PI3K/AKT/mTOR signaling pathway. Experimental and Therapeutic Medicine, 19, 1878–1886.

    CAS  PubMed  Google Scholar 

  18. Bosutti, A., & Degens, H. (2015). The impact of resveratrol and hydrogen peroxide on muscle cell plasticity shows a dose-dependent interaction. Scientific Reports, 5, 8093.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Selvaraj, S., Mohan, A., Narayanan, S., Sethuraman, S., & Krishnan, U. M. (2013). Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property. Journal of Medicinal Chemistry, 56, 970–981.

    Article  CAS  PubMed  Google Scholar 

  20. Dey, A., Guha, P., Chattopadhyay, S. & Bandyopadhyay, S. K. (2009). Biphasic activity of resveratrol on indomethacin-induced gastric ulcers. Biochemical and Biophysical Research Communications, 381, 90–95.

    Article  CAS  PubMed  Google Scholar 

  21. Posadino, A. M., Giordo, R., Cossu, A., Nasrallah, G. K., Shaito, A., & Abou-Saleh, H., et al. (2019). Flavin oxidase-induced ROS generation modulates PKC biphasic effect of resveratrol on endothelial cell survival. Biomolecules, 9, 209.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Albani, D., Polito, L., Batelli, S., De Mauro, S., Fracasso, C., & Martelli, G., et al. (2009). The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. Journal of Neurochemistry, 110, 1445–1456.

    Article  CAS  PubMed  Google Scholar 

  23. Zhang, J., Feng, X., Wu, J., Xu, H., Li, G., & Zhu, D., et al. (2014). Neuroprotective effects of resveratrol on damages of mouse cortical neurons induced by β-amyloid through activation of SIRT1/Akt1 pathway. Biofactors, 40, 258–267.

    Article  CAS  PubMed  Google Scholar 

  24. Chen, Y., Zhang, D. Q., Liao, Z., Wang, B., Gong, S., & Wang, C., et al. (2015). Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson’s disease. Molecular Neurodegeneration, 10, 4.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Rascol, O., Fox, S., Gasparini, F., Kenney, C., Di Paolo, T., & Gomez-Mancilla, B. (2014). Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Related Disorders, 20, 947–956.

    Article  PubMed  Google Scholar 

  26. Mudò, G., Mäkelä, J., Di Liberto, V., Tselykh, T. V., Olivieri, M., & Piepponen, P., et al. (2012). Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cellular and Molecular Life Sciences, 69, 1153–1165.

    Article  PubMed  Google Scholar 

  27. Gaballah, H. H., Zakaria, S. S., Elbatsh, M. M., & Tahoon, N. M. (2016). Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson’s disease. Chemico-Biological Interactions, 251, 10–16.

    Article  CAS  PubMed  Google Scholar 

  28. Kung, H. C., Lin, K. J., Kung, C. T., & Lin, T. K., (2021). Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson’s disease. Biomedicines, 9, 918.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by Dongguan Social Development Key Project (202050715024222) and Guangdong Medical Research Foundation Project (B2021446).

Author information

Authors and Affiliations

  1. Department of Neurology, Dongguan Songshan Lake Central Hospital, Affiliated Hospital of Guangdong Medical University, Dongguan, China

    Yuhan Zhang

  2. Department of Histology and Embryology, College of Basic Medicine, Guangdong Medical University, Dongguan, China

    Hongsheng Guo

  3. Pharmacology Department, School of Pharmacy, Guangdong Medical University, Dongguan, China

    Hui Fu

Authors
  1. Yuhan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongsheng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YH.Z. and HS.G. designed the study, interpreted the data and drafted and revised the manuscript. H.F. provided statistical analyses and interpreted the results.

Corresponding author

Correspondence to Hongsheng Guo.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Guo, H. & Fu, H. Protective Effect of Resveratrol Combined with Levodopa Against Oxidative Damage in Dopaminergic Neurons. Cell Biochem Biophys (2024). https://doi.org/10.1007/s12013-024-01233-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12013-024-01233-9

Keywords

Search

Navigation